Display options
Cite
Kandolf-Sekulovic L, Peris K, Stratigos A, et al. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. J Eur Acad Dermatol Venereol. 2021;35(5):1119-1132doi: 10.1111/jdv.17086.
Kandolf-Sekulovic, L., Peris, K., Stratigos, A., Hauschild, A., Forsea, A. M., Lebbe, C., Lallas, A., Grob, J. J., Harwood, C., Gogas, H., Rutkowski, P., Olah, J., Kelleners-Smeets, N. W. J., Paoli, J., Dummer, R., Moreno-Ramirez, D., Bastholt, L., Putnik, K., Karls, R., Hoeller, C., Vandersleyen, V., Vieira, R., Arenberger, P., Bylaite-Buckinskiene, M., Ocvirk, J., Situm, M., Weinlich, G., Banjin, M., Todorovic, V., Ymeri, A., Zhukavets, A., & Garbe, C. (2021). Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. Journal of the European Academy of Dermatology and Venereology : JEADV, 35(5), 1119-1132. https://doi.org/10.1111/jdv.17086
Kandolf-Sekulovic, L, et al. "Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries." Journal of the European Academy of Dermatology and Venereology : JEADV vol. 35,5 (2021): 1119-1132. doi: https://doi.org/10.1111/jdv.17086
Kandolf-Sekulovic L, Peris K, Stratigos A, Hauschild A, Forsea AM, Lebbe C, Lallas A, Grob JJ, Harwood C, Gogas H, Rutkowski P, Olah J, Kelleners-Smeets NWJ, Paoli J, Dummer R, Moreno-Ramirez D, Bastholt L, Putnik K, Karls R, Hoeller C, Vandersleyen V, Vieira R, Arenberger P, Bylaite-Buckinskiene M, Ocvirk J, Situm M, Weinlich G, Banjin M, Todorovic V, Ymeri A, Zhukavets A, Garbe C. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. J Eur Acad Dermatol Venereol. 2021 May;35(5):1119-1132. doi: 10.1111/jdv.17086. Epub 2021 Feb 10. PMID: 33326646.
Copy Download .nbib Format: NLM
Share it on

J Eur Acad Dermatol Venereol. 2021 May;35(5):1119-1132. doi: 10.1111/jdv.17086. Epub 2021 Feb 10.

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries.

Journal of the European Academy of Dermatology and Venereology : JEADV

L Kandolf-Sekulovic, K Peris, A Stratigos, A Hauschild, A-M Forsea, C Lebbe, A Lallas, J-J Grob, C Harwood, H Gogas, P Rutkowski, J Olah, N W J Kelleners-Smeets, J Paoli, R Dummer, D Moreno-Ramirez, L Bastholt, K Putnik, R Karls, C Hoeller, V Vandersleyen, R Vieira, P Arenberger, M Bylaite-Buckinskiene, J Ocvirk, M Situm, G Weinlich, M Banjin, V Todorovic, A Ymeri, A Zhukavets, C Garbe

Affiliations

  1. Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
  2. Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
  3. 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  4. Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany.
  5. Elias University Hospital Bucharest, Carol Davila University of Medicine and Pharmacy, Bucuresti, Romania.
  6. APHP Dermatology Department, University Paris 7 Diderot, INSERM U976, Paris, France.
  7. First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
  8. Service de Dermatologie et Cancérologie Cutanée, Hopital de la Timone, Marseille, France.
  9. Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  10. 1st Department of Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  11. Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
  12. Department of Oncotherapy, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  13. Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands.
  14. Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  15. UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, Switzerland.
  16. Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  17. Department of Oncology, Odense University Hospital, Odense, Denmark.
  18. North Estonia Medical Centre, Tallinn, Estonia.
  19. Derma Clinic Riga, Riga, Latvia.
  20. Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  21. Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  22. Department of Dermatology, Medical Faculty, University of Coimbra, Coimbra, Portugal.
  23. Department of Dermatovenereology, Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  24. Department of Dermatology, Vilnius University, Vilnius, Lithuania.
  25. Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  26. Department of Oncology, University Hospital Zagreb, Zagreb, Croatia.
  27. Department of Dermatology, Venerology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
  28. Department of Oncology, University Hospital Sarajevo, Sarajevo, Bosnia and Herzegovina.
  29. Clinic for Oncology and radiotherapy, Podgorica, Montenegro.
  30. University Hospital Mother Theresa, Tirana, Albania.
  31. Belarusian Medical Academy of Postgraduate Education (BelMAPE), Minsk, Belarus.
  32. Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.

PMID: 33326646 DOI: 10.1111/jdv.17086

Abstract

BACKGROUND AND OBJECTIVES: The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements for quality melanoma care. The present study is aimed for the first time to roughly estimate the extent to which these requirements have been met in Europe.

MATERIALS AND METHODS: A web-based survey of experts from melanoma centres in 27 European countries was conducted from 1 February to 1 August 2019. Data on diagnostic techniques, surgical and medical treatment, organization of cancer care and education were collected and correlated with national health and economic indicators and mortality-to-incidence ratio (MIR) as a surrogate for survival. Univariate linear regression analysis was performed to evaluate the correlations. SPSS software was used. Statistical significance was set at P < 0.05.

RESULTS: The MIR was lower in countries with a high health expenditure per capita and with a higher numbers of general practitioners (GPs) and surgeons (SURG) per million inhabitants. In these countries, GPs and dermatologists (DER) were involved in melanoma detection; high percentage of DER used dermatoscopy and were involved in the follow-up of all melanoma stages; both medical oncologists (ONC) and dermato-oncologists administered systemic treatments; and patients had better access to sentinel lymph node biopsy and were treated within multidisciplinary tumour boards.

CONCLUSION: Based on these first estimates, the greater involvement of GPs in melanoma detection; the greater involvement of highly trained DER in dermatoscopy, dermatosurgery, follow-up and the systemic treatment of melanoma; and the provision of ongoing dermato-oncology training for pathologists, SURG, DER and ONC are necessary to provide an optimal melanoma care pathway. A comprehensive analysis of the melanoma care pathway based on clinical melanoma registries will be needed to more accurately evaluate these first insights.

© 2020 European Academy of Dermatology and Venereology.

References

  1. Sacchetto L, Zanetti R, Comber H et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92: 108-118. - PubMed
  2. Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-387. - PubMed
  3. Stang A, Khil L, Kajüter H et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol 2019; 33: 6-10. - PubMed
  4. Leiter U, Keim U, Eigentler T et al. Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Invest Dermatol 2017; 137: 1860-1867. - PubMed
  5. Crocetti E, Mallone S, Robsahm TE et al. EUROCARE-5 Working Group: Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2179-2190. - PubMed
  6. Forsea AM, Del Marmol V, Stratigos A, Geller AC. Melanoma prognosis in Europe:far from equal. Br J Dermatol 2014; 171: 179-182. - PubMed
  7. Wouters MW, Michielin O, Bastiaannet E et al. ECCO essential requirements for quality cancer care: melanoma. Crit Rev Oncol Hematol 2018; 122: 164-178. - PubMed
  8. NICE Pathways: managing melanoma NICE, 2020. Available at: http://pathways.nice.org.uk/pathways/melanoma - PubMed
  9. Optimal cancer care pathway for people with melanoma. Cancer Council Australia. Available at: www.cancer.org.au/ocp. - PubMed
  10. Trakatelli M, Siskou S, Proby C et al. EPIDERM. The patient journey: a report of skin cancer care across Europe. Br J Dermatol 2012; 167: 43-52. - PubMed
  11. DERMASurvey, European Dermatology Health Care Survey 2013. Institute for Health Services Research in Dermatology and Nursing. Available at: https://www.dermasurvey.eu/derma-survey/ - PubMed
  12. Forsea AM, Tschandl P, Zalaudek I et al. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey. J Eur Acad Dermatol Venereol 2017; 31: 1148-1156. - PubMed
  13. Forsea AM, Tschandl P, del Marmol V, Zalaudek I, Soyer HP, Geller AC et al. Factors driving the use of dermoscopy in Europe: a pan-European survey. Br J Dermatol 2016; 175: 1329-1337. - PubMed
  14. Mathew A. Global survey of clinical oncology workforce. J Glob Oncol 2018; 4: 1-12. - PubMed
  15. Kandolf Sekulovic L, Guo J, Agarwala S et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer 2018; 104: 201-209. - PubMed
  16. World Bank Group. Available at: http://www.worldbank.org/. - PubMed
  17. Healthcare personnel statistics - physicians. European Commission report, 2017. Available at: https://ec.europa.eu/eurostat. - PubMed
  18. European Cancer Information system - incidence and mortality estimates. Available at: https://ecis.jrc.ec.europa.eu/. - PubMed
  19. Mortality to incidence ratio. Available at: https://ncci.canceraustralia.gov.au/outcomes/mortality-incidence-ratio/mortality-incidence-ratio. - PubMed
  20. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403. - PubMed
  21. Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014; 170: 11-19. - PubMed
  22. Barbaric J, de Vries E, Bray FI et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-126. - PubMed
  23. Znaor A, van den Hurk C, Primic-Zakelj M et al. Cancer incidence and mortality patterns in Southeastern Europe in the last decade: gaps persist compared with the rest of Europe. Eur J Cancer 2013; 49: 1683-1691. - PubMed
  24. Hübner J, Hübner F, Terheyden P, Katalinic A. Turning point in skin cancer mortality: an analysis of the trend in Germany from 1998 to 2017. Hautarzt 2019; 70: 989-992. - PubMed
  25. Stratigos AJ, Forsea AM, van der Leest RJ et al. Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol 2012; 167: 99-104. - PubMed
  26. Fleming NH, Grade MM, Bendavid E. Impact of primary care provider density on detection and diagnosis of cutaneous melanoma. PLoS One 2018; 13: e0200097. - PubMed
  27. Hopkins ZH, Moreno C, Carlisle R, Secrest AM. Melanoma prognosis in the United States: identifying barriers for improved care. J Am Acad Dermatol 2019; 80: 1256-1262. - PubMed
  28. Duarte AF, da Costa-Pereira A, Del-Marmol V, Correia O. Are general physicians prepared for struggling skin cancer? Cross-sectional study. J Cancer Educ 2018; 33: 321-324. - PubMed
  29. Argenziano G, Giacomel J, Abramavicus A et al. Improving triage and management of patients with skin cancer: challenges and considerations for the future. Expert Rev Anticancer Ther 2012; 12: 609-621. - PubMed
  30. Moscarella E, Lallas A, Longo C et al. Five-point checklist for skin cancer detection in primary care. G Ital Dermatol Venereol 2019; 154: 523-528. - PubMed
  31. Minicozzi P, Walsh PM, Sánchez MJ et al. EUROCARE-5 Working Group. Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis? Eur J Cancer 2018; 93: 127-137. - PubMed
  32. Lipworth AD, Park JM, Trefrey BL et al. Urgent access to a specialty care melanoma clinic is associated with a higher rate of melanoma detection. J Am Acad Dermatol 2011; 64: 1060-1067. - PubMed
  33. Pacifico MD, Pearl RA, Grover R. The UK government two-week rule and its impact on melanoma prognosis: an evidence-based study. Ann R Coll Surg Engl 2007; 89: 609-615. - PubMed
  34. Pacifico MD, Grover R, Sanders R. Use of an early-detection strategy to improve disease control in melanoma patients. Br J Plast Surg 2004; 57: 105-111. - PubMed
  35. Lynch M, Tierney E, Roche L et al. Melanoma diagnosis and management after the introduction of a pigmented lesion clinic in the Mid-West of Ireland. Ir J Med Sci 2017; 186: 671-675. - PubMed
  36. Carli P, De Giorgi V, Nardini P et al. Melanoma detection rate and concordance between self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in Italy. Br J Dermatol 2002; 146: 261-266. - PubMed
  37. Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 2015; 119: 464-474. - PubMed
  38. Forsea AM. Cancer registries in Europe - going forward is the only option. Ecancermedicalscience. 2016; 10: 641. - PubMed
  39. European Network of Cancer Registries. Available at: https://www.encr.eu. - PubMed

MeSH terms

Publication Types